Gaithersburg-based Emergent BioSolutions has made the decision to cut 400 jobs and scale back operations at some its facilities, instead focusing on core products such as overdose reversal nasal spray Narcan and anthrax vaccines. The company is also eliminating its chief operating officer (COO) position. According to WTOP, “the job cuts are at Emergent’s Bayview facility in Baltimore, at its drug production facility in Rockville, as well as another facility in Canton, Massachusetts.”
In March, the FDA granted the over-the-counter approval of Narcan to Emergent BioSolutions. It became the first naloxone product approved for use without a prescription. “Emergent’s business pivot is expected to result in yearly savings of more than $100 million, the company explained. The moves will cost Emergent around $20 million—costs it expects to incur in the third quarter of 2023.” according to FiercePharma.
Featured photo courtesy of Google Maps.
Recent Stories
“More Snow, Chance For Blizzards” – FOX5 “Big Winter” – NBC4 “More snow this winter than any other season over the last 5 years” – ABC7 “Above Average Snowfall For Entire DMV” –…
Per the Maryland Attorney General’s Office: Maryland Attorney General Anthony G. Brown has joined a coalition of 17 other Attorneys General supporting California’s efforts to restrict the capacity of firearms…
Per Montgomery County: “Montgomery County Executive Marc Elrich and the Montgomery County Council are recognizing the contributions of Civil Right legend Rosa Parks by proclaiming the month of December as…
Per MCPD: “Detectives from the Montgomery County Department of Police – Financial Crimes Section are investigating an identification fraud and attempted theft that occurred on Friday, November 24, 2023, at…
